In POCHER, the study showed that cetuximab combined with FOLFOXIRI administered as conversion chemotherapy can achieve 60% of the R0 resection rate in patients with initially unresectable liver metastases from wild-type RAS/BRAF colorectal cancer [16]. The gene discussed is BRAF; the disease is colorectal cancer.